Omega-3 ( DrugBank: Omega-3 )

7 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	3
46	悪性関節リウマチ	4
49	全身性エリテマトーデス	4
66	IgA腎症	2
79	家族性高コレステロール血症（ホモ接合体）	1
96	クローン病	1
299	嚢胞性線維症	2

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-003147-19-GR (EUCTR)	18/07/2016	25/05/2016	To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS).	Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Controlled, Add-on with Interferon Beta, Trial of Efficacy and Safety. - Efficacy and Safety study of NEUROASPIS PLP10® versus placebo	Relapsing-Remitting Multiple Sclerosis (RRMS) MedDRA version: 19.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NEUROASPIS PLP10® INN or Proposed INN: FISH OIL,RICH IN OMEGA 3 ACIDS Other descriptive name: FISH OIL, RICH IN OMEGA-3-ACIDS INN or Proposed INN: BORAGE OIL 20% GLA Other descriptive name: BORAGE OIL INN or Proposed INN: beta-Carotene Other descriptive name: BETACAROTENE INN or Proposed INN: Gamma-tocopherol	PALUPA Medical Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	220	Phase 3	Greece
2	NCT02133664 (ClinicalTrials.gov)	June 2014	6/5/2014	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Multiple Sclerosis;Cognition	Drug: lipoic acid and omega-3 fatty acids;Drug: Placebo	Oregon Health and Science University	National Multiple Sclerosis Society	Completed	18 Years	65 Years	All	54	Phase 1/Phase 2	United States
3	NCT00360906 (ClinicalTrials.gov)	December 2004	4/8/2006	Omega-3 Fatty Acid Treatment in Multiple Sclerosis	Omega-3 Fatty Acid Treatment in Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Triomar™ (omega-3 fatty acids)	Haukeland University Hospital	The Multiple Sclerosis National Competence Centre;The Norwegian Multiple sclerosis Society;Pronova BioPharma;Serono Nordic;Amersham Health	Completed	18 Years	55 Years	Both	100	Phase 2/Phase 3	Norway

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04586933 (ClinicalTrials.gov)	December 10, 2020	22/9/2020	Nutrition in Rheumatic Diseases	Nutritional Intervention in Rheumatic Diseases: Effect of Marine Omega-3 Fatty Acids and Individual Dietary Guidance	Spondyloarthritis;Rheumatoid Arthritis;Polyarthritis	Dietary Supplement: Omega-3;Dietary Supplement: Placebo (soya);Behavioral: Dietary guidance	Haukeland University Hospital	GC Rieber Oils AS	Recruiting	18 Years	75 Years	All	120	N/A	Norway
2	NCT01618019 (ClinicalTrials.gov)	November 2010	8/6/2012	N-3 PUFA and Rheumatoid Arthritis in Korea	Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Dietary Supplement: Omega-3 fatty acid;Dietary Supplement: Placebo	Hanyang University	NULL	Completed	18 Years	80 Years	All	109	N/A	Korea, Republic of
3	NCT00399282 (ClinicalTrials.gov)	October 2006	13/11/2006	Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis	Comparison of the Effects of Simultaneous Administration of Vitamin E and Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Omega-3 and Vitamin E supplementation	Shahid Beheshti Medical University	NULL	Completed	16 Years	75 Years	Both	75	Phase 1	Iran, Islamic Republic of
4	NCT00412256 (ClinicalTrials.gov)	September 2004	15/12/2006	Omegaven in Patients With Rheumatoid Arthritis (ORA-Trial)	Clinical Trial to Evaluate the Effect of Parenteral Supplementation With Omega-3-Fatty Acids in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Omegaven (10% fish-oil emulsion; Fresenius-Kabi)	Humanis Klinikum Niederosterreich	NULL	Completed	18 Years	N/A	Both	60	Phase 3	Austria

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03626311 (ClinicalTrials.gov)	October 23, 2018	6/6/2018	Omega-3 Replacement With Krill Oil in Disease Management of SLE	A Double-Blind, Placebo-Controlled Randomized, Multicenter Study to Assess Changes in Omega-3 Index in Erythrocytes and Health Benefit After 24 Weeks of Daily Consumption of AKBM-3031 (Omega-3 Phospholipids From Krill), Followed by a 24 Week Open-Label Extension, in Patients With Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus (SLE)	Dietary Supplement: AKBM-3031;Other: Placebo	Aker Biomarine Antarctic AS	Ampel BioSolutions, LLC	Completed	18 Years	N/A	All	76	N/A	United States;Canada
2	NCT02021513 (ClinicalTrials.gov)	January 2012	13/12/2013	Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus	Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Dietary Supplement: Fish Oil;Dietary Supplement: Olive Oil	University of Texas Southwestern Medical Center	NULL	Completed	18 Years	64 Years	Both	50	Phase 2	United States
3	NCT00828178 (ClinicalTrials.gov)	February 2009	22/1/2009	Efficacy of Fish Oil in Lupus Patients	A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE.	Systemic Lupus Erythematosus	Drug: Omega-3;Device: flow-mediated dilation of the brachial artery;Other: corn starch	Michelle Petri M.D.,MPH	NULL	Completed	18 Years	N/A	All	106	Phase 4	United States
4	EUCTR2004-004404-21-GB (EUCTR)	10/12/2004	17/02/2005	Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus	Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus	Systemic Lupus Erythematosus	Trade Name: Omacor Product Name: Omacor INN or Proposed INN: Eicosapentaenoic acid INN or Proposed INN: Docosahexaenoic acid INN or Proposed INN: alpha-tocopherol	GreenPark Healthcare Trust	Queens University Belfast	Not Recruiting			Female: yes Male: yes	60	Phase 4	United Kingdom

66. IgA腎症

臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00498368 (ClinicalTrials.gov)	February 2009	9/7/2007	Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy	A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy	IgA Nephropathy	Drug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement	Mayo Clinic	Ohio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;Biogen	Completed	18 Years	70 Years	All	34	Phase 4	United States
2	NCT00549692 (ClinicalTrials.gov)	November 2007	25/10/2007	Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy	Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy	IgA Nephropathy	Drug: Omega-3 fatty acid ethylester90	Kuhnil Pharmaceutical Co., Ltd.	Pronova BioPharma ASA	Completed	18 Years	N/A	Both	152	Phase 3	Korea, Republic of

79. 家族性高コレステロール血症（ホモ接合体）

臨床試験数 : 145 / 薬物数 : 114 - (DrugBank : 26) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 17

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03510715 (ClinicalTrials.gov)	August 31, 2018	18/4/2018	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia	An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia	Hypercholesterolemia	Drug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: Lovastatin	Sanofi	Regeneron Pharmaceuticals	Completed	8 Years	17 Years	All	18	Phase 3	Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00074542 (ClinicalTrials.gov)	September 2002	15/12/2003	An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease	A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease	Crohn's Disease	Drug: Epanova™ (Omega-3 Free Fatty Acids)	Tillotts Pharma AG	NULL	Completed	16 Years	N/A	Both	364	Phase 3	United States;Canada

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-004155-38-BE (EUCTR)	21/10/2008	23/09/2008	Biochemical effects of a long-term supplementation with omega-3 polyunsaturated fatty acids in cystic fibrosis - Omega 3 study	Biochemical effects of a long-term supplementation with omega-3 polyunsaturated fatty acids in cystic fibrosis - Omega 3 study	cystic fibrosis MedDRA version: 8.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Product Name: Omega 3 Premium Other descriptive name: OMEGA-3-ACID TRIGLYCERIDES	Hôpital Universitaire Des Enfants Reine Fabiola (H.U.D.E.R.F.)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80		Belgium
2	NCT00959010 (ClinicalTrials.gov)	October 2008	13/8/2009	Omega 3 Supplementation in Cystic Fibrosis Patients	Biochemical Effects of a Long-term Supplementation With Omega-3 Polyunsaturated Fatty Acids in Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: omega-3 triglycerides;Dietary Supplement: Placebo	Queen Fabiola Children's University Hospital	NULL	Completed	6 Years	60 Years	Both	15	Phase 3	Belgium

先頭へ